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Available online 31 October 2016Warfarin resistance is a rare but an important clinical problem in patients requiring anticoagulation. Here we re-
port a male patient with a mechanical aortic prosthetic valve who did not have a target level of therapeutic
anticoagulation on warfarin. A pharmaco-genetic testing revealed VKORC1 A/G and CYP2C9 *1*1 genotype. His
prothrombin time level with international normalization ratio (INR) was 1–1.3 on warfarin 80 mg per day.
Phenprocoumonwas not successful to increase INR level. He has been given enoxaparine BID (1mg/kg) without
any thromboembolic events at follow-up. Although VKORC1 and CYP2C9 genes are twomajor genetic factors re-
sponsible for this clinical situation, more studies seem to be necessary to explain this phenomenon.
The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. This is an open access article
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Warfarin is a widely used oral anticoagulant with a narrow thera-
peutic window and high inter-individual variability. Patients require
different dosages of warfarin for a target international normalization
ratio (INR) level, but 95% of them need more than 1 and less than
9 mg. Patients requiring 9 mg or more warfarin are therefore classiﬁed
as warfarin-resistant.1Case report
The subject is a 35-year-oldmale patientwithmechanical aortic pros-
thetic valve. After surgery, his warfarin dose is gradually increased to
80 mg daily since an optimal INR level is not achieved at usual dosages.
Accordingly, we thought the patient had warfarin resistance. We investi-
gated possible causes of acquired resistance. He is compliant with the
therapy and taked no concurrent medications which interact with
warfarin. He had no gastrointestinal disorders. His diet did not contain
excessive amount of vitamin K. His anticoagulant switched to
phenprocoumon which has longer half-life than warfarin. However, the
patient did not have targeted INR levels. He is started enoxaparine twice
daily (1 mg/kg) therapy. He experienced no thromboembolic events.
Warfarin resistance can be either acquired or hereditary. Possible
causes of acquired resistance include enzymatic induction of warfarindiovascular Academy.
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ction and hosting by Elsevier B.V. Thmetabolism by other drugs, enhanced dietary intake of vitamin K, non-
compliance with therapy and hypothyroidism.2
Genetic factors are contemplated to play role in determining opti-
mum dose for an individual. Studies have demonstrated the effect of
CYP2C9 (cytochrome P450) and VKORC1 (vitamin K epoxide reductase
complex) gene polymorphisms on the dosages of oral coumarin antico-
agulants. Cytochrome P450 2C9 enzyme is involved in the elimination
of warfarin. Allelic variants of CYP2C9 gene, CYP2C9*2(Arg144Cys)
and CYP2C9*3 (Ile359Leu), have less catalytic activity than the wild
type CYP2C9*1(Arg144/Ile359). The presence of these variants in an in-
dividual is thus expected to lower the requirements of the drug.3
Several years ago, VKORC1 has been identiﬁed as the gene encoding
vitaminK epoxide reductase (VKOR) - the target protein for coumarin de-
rivatives likewarfarin or phenprocoumon.4 The vitaminKoxidoreductase
(VKOR) is an integral membrane protein that reduces vitamin K to sup-
port the carboxylation and consequent activation of vitamin K-
dependent proteins.5 Heterozygous VKORC1 missense mutations have
been identiﬁed in individuals who are resistant to warfarin and homozy-
gous mutations have been reported in families with combined deﬁciency
of vitamin-K-dependent clotting factors type 2 (MIM 607473).VKORC1
missensemutations alter vitamin-K epoxide reductase activity and, there-
fore, play a considerable role in the warfarin-resistant phenotype.6
Patients with G allele for VKORC1-1639GNA have a signiﬁcantly
higher number of thromboembolic complications per month during
therapy. VKORC1-1639GNA, age, CYP2C9*3, and smoking status explain
43.4% of the overall variability in the warfarin dose.7
In recent years, Ozer et al. have studied the impact of CYP2C9 and
VKORC1 genetic polymorphism on warfarin dose requirements in
adult Turkish population. The mean warfarin daily dose requirement
was higher in CYP2C9 homozygous wild-type patients, compared tois is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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iant *2 allele and highest in patients with the VKORC1–1639 GG geno-
type compared to those with the GA genotype and the AA genotype.
The time to therapeutic INR was longer in CYP2C9homozygous wild-
type patients compared with those with the variant *2 and *3 alleles,
and longer in patients with the VKORC1 (position−1639) GG genotype
compared with those with the GA genotype and the AA genotype.8
In the present case, pharmacogenetic testing revealed that our pa-
tient carried VKORC1 A/G variant and CYP2C9 *1*1wild type. This geno-
type is expected to require higher doses of warfarin for adequate anti-
coagulation. Despite increasing warfarin doses over ranges in dose-
prediction algorithms, the patient did not reach a target INR level of 2
to 3. His INR levels remained between 1.0 and 1.3, quite under thera-
peutic levels. His anticoagulant was switched to phenprocoumon,
which has a longer half-life than warfarin. It did not increase INR levels
either. Therefore, he is currently being treated with enoxaparine twice
daily. He has experienced no thromboembolic events so far.
In patients requiring high dose warfarin for target anticoagulant ef-
fect, polymorphisms of VKORC1 and CYP2C9 genes should be consid-
ered and they should be investigated. Alternative anticoagulant agents
like enoxaparine can be used in such patients.References
1. Routledge PA, Shetty HGM, White JP, Collins P. Case studies in therapeutics: warfarin
resistance and inefﬁcacy in a man with recurrent thromboembolism, and anticoagu-
lant associated priapism. BR J Clin Pharmacol 1998;46(4):343–346.
2. Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (S)-warfarin in a
warfarin-resistant subject. Br J Clin Pharmacol 1993;35(3):327–330.
3. Kaur A, Khan F, Agrawal SS, Kapoor A, Agarwal SK, Phadke SR. Cytochrome P450
(CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GbA) gene
polymorphisms & their effect on acenocoumarol dose in patients with mechanical
heart valve replacement. Indian J Med Res 2013;137(1):203–209.
4. Müller E, Keller A, Fregin A, CR M, Rost S. Conﬁrmation of warfarin resistance of natu-
rally occurring VKORC1 variants by coexpression with coagulation factor IX and in
silico protein modelling. BMC Genet 2014;4:15–17.
5. RishavyMA, Usubalieva A, Hallgren KW, Berkner KL. Novel insight into themechanism
of the vitamin K oxidoreductase (VKOR) electron relay through Cys43 and Cys51 re-
duces VKOR to allow vitamin K reduction and facilitation of vitamin K-dependent pro-
tein carboxylation. J Biol Chem 2011;286(9):7267–7278.
6. Scott SA, Edelmann L, Kornreich R, RJ D. Warfarin pharmacogenetics: CYP2C9 and
VKORC1 genotypes predict different sensitivity and resistance frequenciesin the Ash-
kenazi and Sephardi Jewish populations. Am J Hum Genet 2008;82:495–500.
7. Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary OA. Factors affecting warfarin dose re-
quirements and quality of anticoagulation in adult Egyptian patients: role of gene
polymorphism. Ir J Med Sci 2014;183(2):161–172.
8. Ozer N, Cam N, Tangurek B, et al. The impact of CYP2C9 and VKORC1 genetic polymor-
phism and patient characteristics upon warfarin dose requirements in an adult Turk-
ish population. Heart Vessel 2010;25:155–162.
